TEVA ▲ +4.0% - Teva Pharmaceutical Industries Limited $TEVA Wells Fargo raised the firm's price target on First Tracks Biotherapeutics (TRAX) to $62 from $55 and keeps an Overweight rating on the shares. With Teva (TEVA) and Argenx (ARGX) both demonstrating efficacy in celiac disease, this further increases the firm's confidence in ANB033's potential. Wells increases its probability of success and views ANB033's upcoming Q4 2026 and Q1 2027 datasets as opportunities to establish differentiation. 09-OCT-2026 08:18 AM ET